Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Allergy Therapeutics plc is a commercial biotechnology company specializing in the diagnosis and treatment of allergic disorders, with particular focus on immunotherapy solutions. The company develops and markets both injectable and sublingual allergen-specific immunotherapies designed to treat pollen-related allergies, such as those caused by grasses, weeds, and trees, as well as offering a suite of diagnostic products. Its portfolio features innovative treatments including Pollinex Quattro, Oralvac, Venomil, Synbiotics, and Acarovac Plus, with new pipeline candidates like Grass MATA MPL for grass pollen allergies and VLP Peanut, a short-course vaccine targeting peanut allergies. Allergy Therapeutics emphasizes transformative patient outcomes by addressing the underlying cause of allergies rather than merely managing symptoms, supporting its approach with aluminium-free, ultra-short course vaccines that promote convenience and adherence. Furthermore, the company leverages unique adjuvant technologies that not only advance allergy immunotherapy efficacy but also hold promise for use in immune responses related to cancer and infectious disease. Operating across several European markets and internationally, Allergy Therapeutics plc holds a significant role in the healthcare sector, driving innovation in specialty pharmaceuticals and expanding access to advanced immunological treatments worldwide.